D-Day approaching for Cell Therapeutics' pixantrone

On 10 February 2010, members of the FDA's Oncologic Drugs Advisory Committee will meet to hear testimony and debate whether or not to approve Cell Therapeutics' application to market pixantrone, the company's experimental drug to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

For Cell Therapeutics, it's fairly safe to say that the fate of the company relies on pixantrone's approval, which while not a sure thing, is nonetheless very likely. The drug has been proven to be fairly effective in tumor reduction and it seems to have a low cardiac toxicity profile. It has not been shown to extend patients' lives; fortunately for Cell Therapeutics, and perhaps not so fortunately for future patients, FDA approval doesn't hinge on this all-important factor.

By Ross Bonander

More on pixantrone from Cell Therapeutics.

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap